These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24423299)

  • 61. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia.
    Souders CA; Maynard SE; Yan J; Wang Y; Boatright NK; Sedan J; Balyozian D; Cheslock PS; Molrine DC; Simas TA
    Int J Mol Sci; 2015 Jun; 16(6):12436-53. PubMed ID: 26042465
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia.
    Lee ES; Oh MJ; Jung JW; Lim JE; Seol HJ; Lee KJ; Kim HJ
    J Korean Med Sci; 2007 Feb; 22(1):94-8. PubMed ID: 17297258
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia.
    Andrade D; Kim M; Blanco LP; Karumanchi SA; Koo GC; Redecha P; Kirou K; Alvarez AM; Mulla MJ; Crow MK; Abrahams VM; Kaplan MJ; Salmon JE
    Arthritis Rheumatol; 2015 Apr; 67(4):977-87. PubMed ID: 25603823
    [TBL] [Abstract][Full Text] [Related]  

  • 65. TLR9 (Toll-Like Receptor 9) Agonist Suppresses Angiogenesis by Differentially Regulating VEGFA (Vascular Endothelial Growth Factor A) and sFLT1 (Soluble Vascular Endothelial Growth Factor Receptor 1) in Preeclampsia.
    He B; Yang X; Li Y; Huang D; Xu X; Yang W; Dai Y; Zhang H; Chen Z; Cheng W
    Hypertension; 2018 Apr; 71(4):671-680. PubMed ID: 29437897
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of angiotensinogen gene polymorphisms and angiogenic factors with preeclampsia in Chinese women.
    Song C; Xie S; Wang J; Lian J; Diao B; Tang Y
    Gynecol Obstet Invest; 2013; 76(1):64-8. PubMed ID: 23860016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
    Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
    BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia.
    McLaughlin K; Baczyk D; Potts A; Hladunewich M; Parker JD; Kingdom JC
    Hypertension; 2017 Jan; 69(1):180-188. PubMed ID: 27840330
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.
    Jeyabalan A; Powers RW; Durica AR; Harger GF; Roberts JM; Ness RB
    Am J Hypertens; 2008 Aug; 21(8):943-7. PubMed ID: 18566591
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy.
    Nadkarni NA; Rajakumar A; Mokhashi N; Burke SD; Rana S; Salahuddin S; Dang Q; Thadhani R; Krishnan R; Stossel TP; Karumanchi SA
    Pregnancy Hypertens; 2016 Oct; 6(4):333-339. PubMed ID: 27939478
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women.
    Tuzcu ZB; Asicioglu E; Sunbul M; Ozben B; Arikan H; Koc M
    Am J Obstet Gynecol; 2015 Oct; 213(4):533.e1-7. PubMed ID: 26116870
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study.
    Winkler K; Contini C; König B; Krumrey B; Pütz G; Zschiedrich S; Pecks U; Stavropoulou D; Prömpeler H; Kunze M; Markfeld-Erol F
    Pregnancy Hypertens; 2018 Apr; 12():136-143. PubMed ID: 29858106
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
    Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
    Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia.
    March MI; Geahchan C; Wenger J; Raghuraman N; Berg A; Haddow H; Mckeon BA; Narcisse R; David JL; Scott J; Thadhani R; Karumanchi SA; Rana S
    PLoS One; 2015; 10(5):e0126815. PubMed ID: 25965397
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.
    Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prediction of imminent preeclampsia at 35-37 weeks gestation.
    Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of physical activity on placental analytes in nulliparous persons.
    Whorton AE; Pan AY; Palatnik A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jan; 292():158-162. PubMed ID: 38016416
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
    Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
    Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.